Clinical trials: Neuropathic Pain
Back Pain, Low Back Pain
Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.
This was a clinical effectiveness trial designed to compare the effectiveness, safety, and tolerability of treatment with tapentadol prolonged release with that of oxycodone/naloxone prolonged release in non-opioid pre-treated…
- Conditions
- Back Pain, Low Back Pain, Neuropathic Pain
- Trial name
- NCT01838616
- Testing
- Tapentadol Prolonged Release, Oxycodone/Naloxone Prolonged Release
- Where
- 50 sites in Austria, Germany and 2 more
- Volunteers
- 367 people
- Sponsor
- Grünenthal GmbH
Diabetic Neuralgia, Diabetic Neuropathies
Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain
This study will compare the efficacy and the safety of ABT-894 (1mg, 2mg or 4mg capsules) administered BID to placebo in the treatment of DNP. Another treatment arm will be Duloxetine 60mg administered once daily (QD).
- Conditions
- Diabetic Neuralgia, Diabetic Neuropathies, Diabetic Neuropathy, Painful, Diabetic Polyneuropathy
- Trial name
- NCT00507936
- Testing
- ABT-894, Duloxetine
- Where
- 49 sites in United States, Canada and 5 more
- Volunteers
- 280 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Pain
Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain
The purpose of the study is to evaluate the efficacy and safety of OraVescent fentanyl treatment compared to placebo treatment monthly over a 12-week treatment period in alleviating breakthrough pain (BTP) in opioid-tolerant…
- Trial name
- NCT00343733
- Testing
- OraVescent Fentanyl
- Where
- 21 sites in United States
- Volunteers
- 120 people
- Sponsor
- Cephalon
Herpes Zoster
A Study to Assess the Burden of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged Sixty Years and Above
The study aims to estimate the incidence of herpes zoster (HZ), proportion of postherpetic neuralgia (PHN) and the economic burden and impact on quality of life, in Japanese adults greater than or equal to sixty years of age.
- Trial name
- NCT01873365
- Testing
- Data collection
- Where
- 14 sites in Japan
- Volunteers
- 448 people
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in France
The purpose of this study is to assess the burden of Herpes zoster (HZ) and post-herpetic neuralgia (PHN) among people ≥ 50 years old in France, in terms of healthcare resources used, medical direct and indirect costs, as well as…
- Trial name
- NCT02487472
- Testing
- Data collection
- Volunteers
- 106 people
- Sponsor
- GlaxoSmithKline
Diabetic Neuropathies
Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy
The purpose of this study is to determine the efficacy and safety of TAK-128, once daily (QD), in treating subjects with diabetic peripheral neuropathy.
- Trial name
- NCT00229437
- Testing
- TAK-128
- Where
- 48 sites in United States, Canada
- Volunteers
- 343 people
- Sponsor
- Takeda
Neuropathic Pain, Pain
Optimized Programming in Spinal Cord Stimulation (SCS) System
The objective of this study is to evaluate extent, location, and perception of paresthesia as a function of anode/cathode configuration.
- Trial name
- OP (NCT00871819)
- Testing
- Precision Spinal Cord Stimulation (SCS)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boston Scientific Corporation
Diabetic Peripheral Neuropathic Pain
Study of the Safety, Tolerability and Efficacy of V3381 in Patients With Diabetic Peripheral Neuropathic Pain
Randomised, double-blind, placebo-controlled, parallel group, multicentre study of oral doses of V3381, titrated to effect. A 2-week single-blind run-in period will be followed by a 13 week double-blind titration and maintenance…
- Trial name
- NCT00794430
- Testing
- V3381
- Where
- 31 sites in United States, Canada and 2 more
- Volunteers
- 161 people
- Sponsor
- Vernalis (R&D) Ltd
Diabetic Neuropathies, Polyneuropathies
Neuropathic Pain Management
This is a prospective, randomized, double blind, comparative, experimental controlled Phase 3 clinical trial to assess the efficacy, safety and superiority of F0343 (gabapentin combined with B vitamins) compared to gabapentin…
- Trial name
- M-F0434 (NCT01263132)
- Testing
- F0434, Gabapentin
- Where
- Mexico
- Volunteers
- 104 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Postherpetic Neuralgia
Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
Evaluation of the efficacy of LX9211 compared to placebo in reducing pain related to postherpetic neuralgia over an 11 week assessment period.
- Trial name
- RELIEF-PHN1 (NCT04662281)
- Testing
- LX9211
- Where
- 32 sites in United States, Czechia and 1 more
- Volunteers
- 79 people
- Sponsor
- Lexicon Pharmaceuticals
Essential Tremor, Parkinson's Disease
Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:
A global post approval study to collect safety and effectiveness data related to ExAblate Neuro for the treatment of certain disorders such as Essential Tremor, Parkinson's Movement Disorders, or Neuropathic Pain within the…
- Conditions
- Essential Tremor, Parkinson's Disease, Movement Disorders, Neuropathic Pain
- Trial name
- NCT03100474
- Where
- 9 sites in United States, Canada and 2 more
- Volunteers
- 500 people
- Sponsor
- InSightec
Postherpetic Neuralgia
Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia
The primary purpose of this study is to evaluate the analgesic efficacy of ADL5747 in participants with postherpetic neuralgia (PHN).
- Trial name
- NCT01058642
- Testing
- ADL5747, Pregabalin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Neuralgia, Postherpetic
A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
The purpose of this study is to evaluate efficacy and safety of pregabalin in the treatment of postherpetic neuralgia in a dose-ranging manner.
- Trial name
- NCT00394901
- Testing
- Pregabalin
- Where
- 39 sites in Japan
- Volunteers
- 372 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Symptomatic Neuroma, Morton's Neuroma
Study of AxoGuard® Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma Pain
Comparing safety, pain, user experience, healthcare economic costs, work productivity, impairment and quality of life outcomes between Axoguard® Nerve Cap and neurectomy in the treatment of symptomatic neuromas in the foot or…
- Conditions
- Symptomatic Neuroma, Morton's Neuroma, Chronic Nerve Pain
- Trial name
- REPOSE (NCT03940963)
- Testing
- AxoGuard® Nerve Cap, Standard Neurectomy
- Where
- 11 sites in United States
- Volunteers
- 86 people
- Sponsor
- Axogen Corporation
Diabetic Peripheral Neuropathic Pain
Efficacy & Safety Study of Nonracemic Methadone for the Relief of Chronic Peripheral Neuropathic Pain
There is a growing evidence that the d-isomer of methadone is effective in treating neuropathic pain while the l-isomer of methadone is the only effective isomer of methadone for treating somatic pain.
- Trial name
- NCT01429181
- Testing
- Non-racemic mixture of methadone HCl
- Volunteers
- 37 people
- Sponsor
- MetaPharm, Inc.
Neuropathic Pain, Diabetes Mellitus, Type 2
A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain
This study is to compare the efficacy and safety of pregabalin sustained release tablet and pregabalin immediate release capsule in type II diabetic patients with peripheral neuropathic pain.
- Trial name
- NCT05624853
- Testing
- pregabalin sustained release tablet, pregabalin immediate release capsule
- Where
- 8 sites in South Korea
- Volunteers
- 130 people
- Sponsor
- Yuhan Corporation
Postherpetic Neuralgia
Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia
The primary objective is to explore whether sensory symptom cluster analysis is useful for predicting treatment response in Postherpetic Neuralgia.
- Trial name
- NCT01603394
- Testing
- pregabalin
- Where
- 9 sites in United States, Austria and 2 more
- Volunteers
- 9 people
- Sponsor
- Pfizer
Pain, Pain, Acute
Assessing Opioid Care Practices Using CPV Patient Simulation Modules
This study will test the quality of opioid-related physician care decisions using a patient-simulation based measurement and feedback approach that combines multiple-choice care decisions with real-time, personalized scoring and…
- Conditions
- Pain, Pain, Acute, Pain, Chronic, Pain, Neuropathic
- Trial name
- NCT04080037
- Testing
- Quality IQ Patient Simulations
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Neuralgia, Postherpetic
Safety and Effectiveness of Repeated Administration of QUTENZA Patches for Treatment of Pain Caused by Nerve Damage
In this study all patients will be treated with the same medicine, the QUTENZA patch. Subjects will receive up to 6 QUTENZA patch applications over 12 months.
- Trial name
- STRIDE (NCT01252160)
- Testing
- QUTENZA
- Where
- 64 sites in Austria, Belgium and 14 more
- Volunteers
- 306 people
- Sponsor
- Astellas Pharma Inc
Neuralgia
Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)
The purpose of the study is to determine the efficacy and safety of Perampanel (E2007) in patients with Post-Herpetic Neuralgia (PHN).
- Trial name
- NCT00592774
- Testing
- E2007 (perampanel)
- Where
- 47 sites in United States, Canada
- Volunteers
- 146 people
- Sponsor
- Eisai Inc.